Nikolaos Kozeis

Nikolaos Kozeis

Auto-generated profile, based on publicly available information

Nikolaos Kozeis

Ophthalmica Eye Institute, Thessaloniki, Greece,

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
SKSpyridon Koronis
Spyridon Koronis
PSPanagiotis Stavrakas
Panagiotis Stavrakas
Miltos O BalidisMiltos O Balidis
Miltos O Balidis
NKNikolaos Kozeis
Nikolaos Kozeis
PTParis G. Tranos
Paris G. Tranos
Macular edema (ME) represents the most common cause for visual loss among uveitis patients. The management of uveitic macular edema (UME) may be challenging, due to its often recalcitrant nature. Corticosteroids remain the mainstay of treatment, through their capability of effectively controlling inflammation and the associated ME. Topical steroids may be effective in milder cases of UME, particularly in edema associated with anterior uveitis. Posterior sub-Tenon and orbital floor steroids, as well as intravitreal steroids often induce rapid regression of UME, although this may be followed by recurrence of the pathology. Intravitreal corticosteroid implants provide sustained release of steroids facilitating regression of ME with less frequent injections. Topical nonsteroidal anti-inflammatory drugs may provide a safe alternative or adjuvant therapy to topical steroids in mild UME, predominantly in cases with underlying anterior uveitis. Immunomodulators including methotrexate, mycophenolate mofetil, tacrolimus, azathioprine, and cyclosporine, as well as biologic agents, notably the anti-tumor necrosis factor-α monoclonal antibodies adalimumab and infliximab, may accomplish the control of inflammation and associated ME in refractory cases, or enable the tapering of steroids. Newer biotherapies have demonstrated promising outcomes and may be considered in persisting cases of UME.

1 March 2017 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
IAIoannis Asproudis
Ioannis Asproudis
NKNikolaos Kozeis
Nikolaos Kozeis
AKAndreas Katsanos
Andreas Katsanos
SJSaurabh Jain
Saurabh Jain
PTParis G. Tranos
Paris G. Tranos
AKAnastasios-Georgios P. Konstas
Anastasios-Georgios P. Konstas
Minimally invasive surgery is rapidly becoming the norm in medicine, as it often leads to better outcomes and earlier rehabilitation. This article reviews the principles and different techniques employed to perform minimally invasive strabismus surgery (MISS). In these techniques, strabismus surgery is performed through keyhole openings, thus reducing the risk of postoperative corneal complications, minimizing postoperative discomfort, and better preserving muscle function. MISS can be used to perform all types of strabismus surgery, namely rectus muscle recessions, resections, plications, reoperations, retroequatorial myopexy, transpositions, oblique muscle recessions, or plications even in the presence of limited motility. Of note, ocular alignment outcomes with MISS versus more traditional techniques have not been compared in randomized trials. Consequently, more controlled evidence is still needed to better delineate the future role and value of MISS in clinical management.

1 September 2009 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AVAthanasios Vardarinos
Athanasios Vardarinos
DZDimitrios Zafeiriou
Dimitrios Zafeiriou
EVEuthymia Vargiami
Euthymia Vargiami
PPPolyxeni Pratsidou-Gertsi
Polyxeni Pratsidou-Gertsi
EKEleutherios Kontopoulos
Eleutherios Kontopoulos
IMIoannis Mavromatis
Ioannis Mavromatis